Fluorescence single particle tracking for the characterization of submicron protein aggregates in biological fluids and complex formulations

Pharmaceutical Research

Volumn 28, Issue 5, 2011, Pages 1112-1120

  Filipe, Vasco ^a,b   Poole, Robert ^a   Kutscher, Marika ^a   Forier, Katrien ^c   Braeckmans, Kevin ^c   Jiskoot, Wim ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

fluorescence single particle tracking; HSA; IgG; protein aggregates; serum and plasma

Indexed keywords

GLUTARALDEHYDE; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN G;

ACCURACY; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; FLUORESCENCE SINGLE PARTICLE TRACKING; HEAT STRESS; INTERMETHOD COMPARISON; MOLECULAR SIZE; NANOPARTICLE TRACKING ANALYSIS; PLASMA; PRIORITY JOURNAL; PROTEIN AGGREGATION; SERUM;

CROSS-LINKING REAGENTS; EXCIPIENTS; FLUORESCENCE; FLUORESCENT DYES; HUMANS; IMMUNOGLOBULIN G; NANOPARTICLES; PARTICLE SIZE; PLASMA; PROTEIN CONFORMATION; SERUM; SERUM ALBUMIN;

EID: 79955605394     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0374-0     Document Type: Article

References (28)

1. ME Cromwell E Hilario F Jacobson 2006 Protein aggregation and bioprocessing AAPS J. 8 E572 E579 17025275 10.1208/aapsj080366 1:CAS:528:DC%2BD28XhtVGltLnJ (Pubitemid 44458092)
2. HC Mahler W Friess U Grauschopf S Kiese 2009 Protein aggregation: pathways, induction factors and analysis J Pharm Sci. 98 2909 2934 18823031 10.1002/jps.21566 1:CAS:528:DC%2BD1MXptl2isb0%3D
3. AS Rosenberg 2006 Effects of protein aggregates: an immunologic perspective AAPS J. 8 E501 E507 17025268 10.1208/aapsj080359 (Pubitemid 44294011)
4. H Schellekens 2002 Bioequivalence and the immunogenicity of biopharmaceuticals Nat Rev Drug Discov. 1 457 462 12119747 10.1038/nrd818 1:CAS:528:DC%2BD38Xkt1Cmur8%3D (Pubitemid 37361488)
5. A Hawe JC Kasper W Friess W Jiskoot 2009 Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress Eur J Pharm Sci. 38 79 87 19540340 10.1016/j.ejps.2009.06.001 1:CAS:528: DC%2BD1MXhtVentb7K
6. JF Carpenter TW Randolph W Jiskoot DJ Crommelin CR Middaugh G Winter, et al. 2009 Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality J Pharm Sci. 98 1201 1205 18704929 10.1002/jps.21530 1:CAS:528:DC%2BD1MXktlSisLs%3D
7. JS Philo 2009 A critical review of methods for size characterization of non-particulate protein aggregates Curr Pharm Biotechnol. 10 359 372 19519411 10.2174/138920109788488815 1:CAS:528:DC%2BD1MXotlCnt7g%3D
8. CT Huang D Sharma P Oma R Krishnamurthy 2009 Quantitation of protein particles in parenteral solutions using micro-flow imaging J Pharm Sci. 98 3058 3071 18937372 10.1002/jps.21575 1:CAS:528:DC%2BD1MXptl2isbg%3D
9. W Fraunhofer G Winter 2004 The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics Eur J Pharm Biopharm. 58 369 383 15296962 10.1016/j.ejpb.2004.03.034 1:CAS:528:DC%2BD2cXmsVGns7c%3D (Pubitemid 39037242)
10. Arakawa T, Wen TJ. Size-exclusion chromatography with on-line light scattering. Curr Protoc Protein Sci. 2001 Chapter 20:Unit 20 26.
11. V Filipe A Hawe W Jiskoot 2010 Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates Pharm Res. 27 796 810 20204471 10.1007/s11095-010-0073-2 1:CAS:528:DC%2BC3cXisl2jtbw%3D
12. K Braeckmans K Buyens W Bouquet-Geerardyn C Vervaet P Joye F De Vos, et al. 2010 Sizing nanomatter in biological fluids by fluorescence Single Particle Tracking Nano Lett. 10 4435 4442 20923181 10.1021/nl103264u 1:CAS:528: DC%2BC3cXht1CmtbbL
13. B Demeule SJ Shire J Liu 2009 A therapeutic antibody and its antigen form different complexes in serum than in phosphate-buffered saline: a study by analytical ultracentrifugation Anal Biochem. 388 279 287 19289095 10.1016/j.ab.2009.03.012 1:CAS:528:DC%2BD1MXkvVWnsrw%3D
14. J Suh KL Choy SK Lai JS Suk BC Tang S Prabhu, et al. 2007 PEGylation of nanoparticles improves their cytoplasmic transport Int J Nanomed. 2 735 741 10.2217/17435889.2.5.735 1:CAS:528:DC%2BD1cXhtFKrt7g%3D (Pubitemid 350268250)
15. S Cao Y Jiang L Narhi 2010 A light-obscuration method specific for quantifying subvisible particles in protein therapeutics Pharmacop Forum. 36 824 834
16. Braeckmans K, Vercauteren D, Demeester J, De Smedt SC. Single particle tracking. In: Diaspro A, editor. Nanoscopy multidimensional optical fluorescence microscopy. Taylor and Francis. 2010.
17. JW Yoo E Chambers S Mitragotri 2010 Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects Curr Pharm Des. 16 2298 2307 20618151 10.2174/138161210791920496 1:CAS:528: DC%2BC3cXhtFertrfI
18. SM Moghimi AC Hunter JC Murray 2001 Long-circulating and target-specific nanoparticles: theory to practice Pharmacol Rev. 53 283 318 11356986 1:CAS:528:DC%2BD3MXkt1Gnurc%3D (Pubitemid 32476118)
19. MM Frank LF Fries 1991 The role of complement in inflammation and phagocytosis Immunol Today. 12 322 326 1755943 10.1016/0167-5699(91)90009-I 1:CAS:528:DyaK38Xht1Kgsrk%3D
20. DT Cheung ME Nimni 1982 Mechanism of crosslinking of proteins by glutaraldehyde II. Reaction with monomeric and polymeric collagen Connect Tissue Res. 10 201 216 6299648 10.3109/03008208209034419 1:CAS:528: DyaL3sXivF2msA%3D%3D (Pubitemid 13234870)
21. R Usha T Ramasami 2005 Structure and conformation of intramolecularly cross-linked collagen Colloids Surf B Biointerfaces. 41 21 24 15698752 10.1016/j.colsurfb.2004.11.001 1:CAS:528:DC%2BD2MXhtVyisrg%3D (Pubitemid 40215480)
22. S Hermeling L Aranha JM Damen M Slijper H Schellekens DJ Crommelin, et al. 2005 Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b Pharm Res. 22 1997 2006 16184451 10.1007/s11095-005-8177-9 1:CAS:528:DC%2BD2MXhtlemtbnP (Pubitemid 41821578)
23. A Gessner R Waicz A Lieske B Paulke K Mader RH Muller 2000 Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption Int J Pharm. 196 245 249 10699728 10.1016/S0378-5173(99)00432-9 1:CAS:528:DC%2BD3cXhtl2qtb4%3D (Pubitemid 30105753)
24. W Wang 2000 Lyophilization and development of solid protein pharmaceuticals Int J Pharm. 203 1 60 10967427 10.1016/S0378-5173(00)00423-3 1:CAS:528:DC%2BD3cXmtVals7w%3D (Pubitemid 30627625)
25. McGoff P, Scher DS. Solution formulation of proteins/peptides. In: McNally EJ, Hastedt JE, editors. Protein formulation and delivery, vol. 175. New York: Informa Healthcare USA, Inc.; 2000.
26. A Braun J Alsenz 1997 Development and use of enzyme-linked immunosorbent assays (ELISA) for the detection of protein aggregates in interferon-alpha (IFN-alpha) formulations Pharm Res. 14 1394 1400 9358552 10.1023/A:1012168621337 1:CAS:528:DyaK2sXntFeht78%3D (Pubitemid 27481070)
27. R Kumarasamy J Bausch D Kopcha S Patel E McGonigle 1994 An enzyme-linked immunosorbent assay (ELISA) for quantitation of adducts of granulocyte- macrophage colony stimulating factor (GM-CSF) and human serum albumin (HSA) in stressed solution mixtures Pharm Res. 11 365 371 8008700 10.1023/A:1018900701657 1:CAS:528:DyaK2cXitVyks78%3D (Pubitemid 24117353)
28. W Wang S Nema D Teagarden 2010 Protein aggregation-Pathways and influencing factors Int J Pharm. 390 89 99 20188160 10.1016/j.ijpharm.2010.02. 025 1:CAS:528:DC%2BC3cXksFShtL8%3D